GlassScriptPhysician profile
Polly A Niravath
NPI 1710123088
$10,504.28
in general payments reported to CMS, 2019-2025
17 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $1,300 · 2021: $1,336 · 2022: $18.91 · 2023: $7,306 · 2024: $172 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,897 · Food and Beverage: $584 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,896.82 |
| Food and Beverage | $584.44 |
| Education | $137.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,614.97 | 2022-2025 | Kisqali |
| Genentech USA, INC. | $2,280.00 | 2023 | Herceptin, Perjeta, Phesgo |
| Tersera Therapeutics LLC | $2,254.32 | 2023 | Zoladex |
| Gilead Sciences, INC. | $1,551.15 | 2021-2025 | Trodelvy |
| Immunomedics, INC. | $1,300.00 | 2020 | |
| Pfizer INC. | $228.38 | 2019-2023 | |
| Aadi Bioscience, INC. | $99.99 | 2023 | Fyarro |
| Stimwave Technologies Incorporated | $51.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.56 | 2023-2024 | Enhertu |
| Tempus Ai, INC | $28.41 | 2025 | Xt Cdx |
| Puma Biotechnology, INC. | $28.24 | 2024 | |
| Merck Sharp & Dohme LLC | $19.63 | 2023 | Dificid, Zerbaxa |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polly Niravath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.